Susan Bobulsky

Susan Bobulsky

Chief Commercial Officer, MRDatAdaptive Biotechnologies· In proxies 2023–2025

Pay in FY2024+17% from the year before · Adaptive Biotechnologies stock +22.3% the same year

Susan Bobulsky was paid $1.7M in FY2024 (Dec), up 17%. Adaptive Biotechnologies stock rose 22.3% that year.

Pay$100 in the stock at the end of FY22 → $78
Pay is from the Summary Compensation Table of each Adaptive Biotechnologies proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Adaptive BiotechnologiesPublic company · 3 yr
    • Chief Commercial Officer, MRD2023 – Present · 3 yrStock in role +297%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?